Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
S SENSORY ORGANS
S01 OPHTHALMOLOGICALS
S01L OCULAR VASCULAR DISORDER AGENTS
S01LA Antineovascularisation agents
S01LA06 Brolucizumab
D11083 Brolucizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Ophthalmic Agents
Ophthalmic Agents, Other
Vascular Endothelial Growth Factor (VEGF) Inhibitor
Brolucizumab
D11083 Brolucizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
13 Agents affecting sensory organs
131 Ophthalmic agents
1319 Others
D11083 Brolucizumab (USAN/INN); Brolucizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Growth factors (RTK-binding)
VEGFA
D11083 Brolucizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11083
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11083
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11083
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11083
